Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy

about

Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy

Item

http://www.wikidata.org/entity/Q58732707

description

scientific article published on 20 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@en

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@nl

type

Item

label

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@en

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@nl

prefLabel

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@en

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@nl

P1476

Apatinib monotherapy for advan ...... rapy or other targeted therapy

@en

P2093

Ning Li

http://www.w3.org/2001/XMLSchema#string

Wei Ou

http://www.w3.org/2001/XMLSchema#string

Zui Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Global cancer statistics, 2012

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

P304

1285-1290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12836

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Si-Yu Wang

P577

2018-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30126078

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

6166085

http://www.w3.org/2001/XMLSchema#string